To further query the how suppressing elevated MYC in cancer cells may affect circadian gene expression, we leveraged publicly available data where PC3 prostate cancer cells, known to have high endogenous (non-amplified) MYC levels [39,40], were treated with the new generation MYC inhibitor MYCi361 [41]. The gene discussed is MYC; the disease is prostate cancer.